Patrick Burnett
Research Subjects
Patrick Burnett has a total of 60 co-authors. Here are the top co-authors by number of shared publications:
David Krupa
Arcutis Biotherapeutics, Inc
3 shared publications- Melinda Gooderham
Department of Dermatology Queens University Peterborough Ontario Canada
3 shared publications Scott Snyder
Arcutis Biotherapeutics, Inc
3 shared publications- Adelaide Ann Hebert
UTHealth McGovern Medical School Houston Texas USA
2 shared publications - David R. Berk
Arcutis Biotherapeutics, Inc
2 shared publications Diane Hanna
Arcutis Biotherapeutics, Inc
2 shared publications
Latest Publications
- Open Access
- 11 June 2026
- Published by Taylor & Francis in Journal of Dermatological Treatment
- Vol. 37 (1) , 1-12
Roflumilast foam versus vehicle foam for seborrheic dermatitis (STRATUM clinical study): a plain language summary
- 11 June 2026
- Published by Taylor & Francis in Journal of Dermatological Treatment
- Vol. 37 (1) , 1-12
Open AccessRoflumilast foam versus vehicle foam for seborrheic dermatitis (STRATUM clinical study): a plain language summary
- Open Access
- 11 June 2026
- Published by Taylor & Francis in Journal of Dermatological Treatment
- Vol. 37 (1) , 2662191
Long-term treatment of atopic dermatitis with roflumilast cream 0.15% in patients aged 6 years or older (INTEGUMENT-OLE clinical study): a plain language summary
- 11 June 2026
- Published by Taylor & Francis in Journal of Dermatological Treatment
- Vol. 37 (1) , 2662191
Open AccessLong-term treatment of atopic dermatitis with roflumilast cream 0.15% in patients aged 6 years or older (INTEGUMENT-OLE clinical study): a plain language summary
- Open Access
- 1 November 2025
- Published by Springer Nature in American Journal of Clinical Dermatology
- Vol. 27 (1) , 189-198
Long-Term Safety and Efficacy of Roflumilast Foam 0.3% in Patients with Seborrheic Dermatitis: A Phase II, Open-Label Trial of up to 52 Weeks
Background The efficacy and safety of once-daily roflumilast foam 0.3%, a potent phosphodiesterase 4 inhibitor, has been demonstrated in patients with seborrheic dermatitis (SD). Objectives To evaluate long-term effects of roflumilast foam 0.3% in patients with SD. Methods A phase II, open-label trial (no. NCT04445987) was conducted in patients (aged ≥ 12 years) with SD who completed a prior roflumilast foam trial or were naïve to roflumilast and vehicle. Patients applied roflumilast foam 0.3% once daily to all affected areas, including the scalp, face, trunk, and intertriginous areas, for 24 or 52 weeks (during the course of the trial, the protocol was amended to extend the duration of treatment from 24 weeks to 52 weeks). The primary endpoints were occurrence of treatment-emergent adverse events (AEs); local tolerability and efficacy (via Investigator Global Assessment [IGA]) were also assessed. Results Overall, 400 patients participated, among whom 62 were enrolled for 52 weeks. AE rates were low, and ≤ 1.1% reported stinging sensation at the application site at each visit. Durable improvement in signs and symptoms of SD was observed at weeks 24 and 52, with 76.0% and 80.4% of patients, respectively, achieving an IGA of clear or almost clear. Conclusions Roflumilast foam 0.3% was well tolerated and improved and/or maintained improvements in signs and symptoms of SD for up to 52 weeks. ClinicalTrials.gov Listing NCT04445987.
- 1 November 2025
- Published by Springer Nature in American Journal of Clinical Dermatology
- Vol. 27 (1) , 189-198
Open AccessLong-Term Safety and Efficacy of Roflumilast Foam 0.3% in Patients with Seborrheic Dermatitis: A Phase II, Open-Label Trial of up to 52 Weeks
Background The efficacy and safety of once-daily roflumilast foam 0.3%, a potent phosphodiesterase 4 inhibitor, has been demonstrated in patients with seborrheic dermatitis (SD). Objectives To evaluate long-term effects of roflumilast foam 0.3% in patients with SD. Methods A phase II, open-label trial (no. NCT04445987) was conducted in patients (aged ≥ 12 years) with SD who completed a prior roflumilast foam trial or were naïve to roflumilast and vehicle. Patients applied roflumilast foam 0.3% once daily to all affected areas, including the scalp, face, trunk, and intertriginous areas, for 24 or 52 weeks (during the course of the trial, the protocol was amended to extend the duration of treatment from 24 weeks to 52 weeks). The primary endpoints were occurrence of treatment-emergent adverse events (AEs); local tolerability and efficacy (via Investigator Global Assessment [IGA]) were also assessed. Results Overall, 400 patients participated, among whom 62 were enrolled for 52 weeks. AE rates were low, and ≤ 1.1% reported stinging sensation at the application site at each visit. Durable improvement in signs and symptoms of SD was observed at weeks 24 and 52, with 76.0% and 80.4% of patients, respectively, achieving an IGA of clear or almost clear. Conclusions Roflumilast foam 0.3% was well tolerated and improved and/or maintained improvements in signs and symptoms of SD for up to 52 weeks. ClinicalTrials.gov Listing NCT04445987.
- Open Access
- 14 May 2025
- Published by Wiley in JEADV Clinical Practice
- Vol. 4 (4) , 719-731
Genital Psoriasis: Shining Light on This Hidden Disease
Background: Psoriasis occurring on the skin of the genital and perigenital regions, including the inguinal creases, vulva, penis, scrotum, perianal area, and the intergluteal cleft, has specific diagnostic and treatment requirements due to the sensitivity and private nature of these areas.Objectives: A multidisciplinary group of 13 US‐based clinicians who are experts in the management of genital psoriasis, the Genital Psoriasis Wellness Consortium, convened to discuss the impact of genital psoriasis on patients focusing on three main domains: (1) physical diagnosis and patient conversations, (2) impact on patient quality of life/interpersonal relationships, and (3) treatment decisions.Methods: A PubMed literature search was conducted, and the Consortium members used the results to formulate their consensus statements using a modified Delphi process, including a nominal group technique. The process included two rounds of virtual subcommittee meetings based on the three domains, followed by surveys to obtain anonymous feedback, and concluded with a final meeting to discuss and finalize the language of the consensus recommendations across all three domains. Three additional psoriasis experts provided feedback on these consensus statements from Canadian, European, and Asian perspectives.Results: Herein, we report our 14 consensus statements and a summary of the supporting data.Conclusions: These consensus statements are meant as a practical resource for clinicians to ensure that symptoms of genital psoriasis are not overlooked. We hope to continue to add to these statements as additional clinical data become available.
- 14 May 2025
- Published by Wiley in JEADV Clinical Practice
- Vol. 4 (4) , 719-731
Open AccessGenital Psoriasis: Shining Light on This Hidden Disease
Background: Psoriasis occurring on the skin of the genital and perigenital regions, including the inguinal creases, vulva, penis, scrotum, perianal area, and the intergluteal cleft, has specific diagnostic and treatment requirements due to the sensitivity and private nature of these areas.Objectives: A multidisciplinary group of 13 US‐based clinicians who are experts in the management of genital psoriasis, the Genital Psoriasis Wellness Consortium, convened to discuss the impact of genital psoriasis on patients focusing on three main domains: (1) physical diagnosis and patient conversations, (2) impact on patient quality of life/interpersonal relationships, and (3) treatment decisions.Methods: A PubMed literature search was conducted, and the Consortium members used the results to formulate their consensus statements using a modified Delphi process, including a nominal group technique. The process included two rounds of virtual subcommittee meetings based on the three domains, followed by surveys to obtain anonymous feedback, and concluded with a final meeting to discuss and finalize the language of the consensus recommendations across all three domains. Three additional psoriasis experts provided feedback on these consensus statements from Canadian, European, and Asian perspectives.Results: Herein, we report our 14 consensus statements and a summary of the supporting data.Conclusions: These consensus statements are meant as a practical resource for clinicians to ensure that symptoms of genital psoriasis are not overlooked. We hope to continue to add to these statements as additional clinical data become available.